Travere Therapeutics Announces Long-Term Results From Ongoing Phase 3 DUPLEX Study Open-Label Extension Of FILSPARI In Treatment Of Focal Segmental Glomerulosclerosis

Loading news article.

Travere Therapeutics Announces Long-Term Results From Ongoing Phase 3 DUPLEX Study Open-Label Extension Of FILSPARI In Treatment Of Focal Segmental Glomerulosclerosis | WAPE

Travere Therapeutics Announces Long-Term Results From Ongoing Phase 3 DUPLEX Study Open-Label Extension Of FILSPARI In Treatment Of Focal Segmental Glomerulosclerosis

Article summary

Related companies

Comments —